Related Experiment Video

Updated: Dec 11, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.5K

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

Lucia Musacchio1, Giuseppe Caruso1, Carmela Pisano2

  • 1Department of Maternal and Child Health and Urological Sciences, University "Sapienza", Policlinico Umberto I, Rome, Italy.

Cancer Management and Research
|August 18, 2020
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for treating advanced endometrial cancer (EC), particularly when combined with other therapies. Research is exploring their efficacy, especially in cancers with DNA repair defects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced endometrial cancer (EC) presents a poor prognosis with limited treatment options.
  • Precision medicine advances have identified targeted therapies like poly (ADP-ribose) polymerase (PARP) inhibitors.
  • PARP inhibitors are increasingly used in gynecological malignancies, showing efficacy in cancers with homologous DNA recombination defects.

Purpose of the Study:

  • To review the current use of PARP inhibitors in endometrial cancer treatment.
  • To summarize preclinical data and ongoing clinical trials for PARP inhibitors in EC.
  • To explore combination treatment strategies involving PARP inhibitors and immune checkpoint inhibitors.

Main Methods:

  • Review of preclinical in vivo and in vitro studies on PARP inhibitors in EC.
  • Analysis of data from clinical trials investigating PARP inhibitors in gynecological cancers.
  • Examination of the role of PTEN and TP53 gene mutations in EC's response to PARP inhibition.

Main Results:

  • PARP inhibitors demonstrate efficacy in cancers with homologous DNA recombination system defects.
  • Preclinical studies indicate promising results for PARP inhibitors in endometrial cancer.
  • Endometrial cancer frequently exhibits mutations (PTEN, TP53) relevant to DNA repair pathways.

Conclusions:

  • PARP inhibitors represent a promising targeted therapy for advanced endometrial cancer.
  • Further research and clinical trials are warranted to establish optimal treatment strategies.
  • Combination therapies, including with immune checkpoint inhibitors, may enhance treatment outcomes for EC.
Keywords:
P53 mutationPARP inhibitorsPTEN mutationendometrial cancerhomologous recombination deficiencyimmune checkpoint inhibitors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

914

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K